Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 11, Issue 2, 2010, Pages 105-113

  Souquet, Pierre Jean ^a   Krzakowski, MacIej ^b   Ramlau, Rodrig ^c   Sun, Xu Shan ^d   Lopez Vivanco, Guillermo ^e   Puozzo, Christian ^f   Pouget, Jean Christophe ^f   Pinel, Marie Claire ^f   Rosell, Rafael ^g  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c GREATER POLAND CANCER CENTRE   (Poland)

^d Hôpital André Bouloche   (France)

^e HOSPITAL DE CRUCES   (Spain)

^f INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Drug drug interaction; Free platinum; Maximum tolerated dose; Neutropenia

Indexed keywords

CISPLATIN; VINFLUNINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; GASTRITIS; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

EID: 77952493884     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.014     Document Type: Article

References (36)

1. Non small Cell Lung Cancer Cooperative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised trials. BMJ 1995; 311:899-909.
2. Dubey S, Schiller JH. Chemotherapy for advanced non-small cell lung cancer. Hematol Oncol Clin N Am 2004; 18:101-114
3. Fahy J, Duflos A, Ribet JP, et al. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 1997; 36:8576-8577
4. Ngan V, Bellman K, Panda D, et al. Novel actions of the antitumour drugs vinflunine and vinorelbine on microtubules. Cancer Res 2000; 60:5045-5051
5. Kruczynski A, Barret JM, Etievant C, et al. Antimiotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid. Biochem Pharmacol 1998; 55:635-648 (Pubitemid 28077822)
6. Etievant C, Barret JM, Kruczynski A, et al. Vinflunine (20'-20'-difluoro-3 ', 4'-dihydrovinorelbine) a novel vinca alkaloid, which particiaptes in P-glycoprotein (Pgp)- mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998; 16:3-17.
7. Ngan VK, Bellman K, Hill BT, et al. Mechanism of mitotic block and inhibition of cell proliferation by semisynthetic vinca alkaloids vinorelbine and its new derivative vinflunine. Mol Pharmacol 2001; 60:225-232
8. Lobert S, Ingram JW, Hill BT, et al. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998; 53:908-915
9. Hill BT, Fiebig H, Waud WR, et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 1999; 35:512-520
10. Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 2003; 14:630-637
11. Bennouna J, Breton JL, Tourani JP, et al. Vinflunine an active chemotherapy for treatment of advanced non-small cell lung cancer previously treated with a platinum based regimen: results of a phase II study. Br J Cancer 2006; 94:1383-1388
12. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-3551
13. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-1531
14. Aita M, Fasola G, Defferrari C, et al. Targeting the VRGF pathway: antiangiogenic strategies in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2008; 68:183-196
15. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234
16. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. (Review) Oncol Rep 2004; 11:559-595
17. Barret JM, Etievant C, Hill B. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 2000; 45:471-476
18. Focan C, Van Heugen JC, Kreutz F, et al. Vinflunine metabolism and disposition in cancer patients. Proc Ann Meet Am Soc Clin Oncol 2002; 21:124a (abstract 495).
19. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization; 1979.
20. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10:239-253
21. National Cancer Institute Common Toxicity Criteria (CTC version 2.0). Final version, 1/30/98; published on April 30, 1999.
22. Beal SL, Sheiner LB. NONMEM User's Guides. San Francisco: NONMEM Project Group, 1989.
23. Nguyen L, Retout S, Mentre F, et al. Population pharmacokinetic of vinflunine from phase I data and evaluation of population sampling designs for further clinical development. PAGE 11 (2002). Abstract 334. Available at: http://www.page-meeting.org/?abstract=334. Accessed: January 1, 2010.
24. Johnson P, Geldart T, Fumoleau P, et al. Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs 2006; 24:223-231
25. Delord JP, Stupp R, Pinel MC, et al. Phase I study of vinflunine given as a 10-minute intravenous (i.v.) infusion on a weekly schedule in patients (pts) with advanced solid tumours. Proc Am Soc Clin Oncol 2001; 20: (abstract 441).
26. Vermorken JB, Stupp R, Nguyen L, et al. Phase I study of i.v. vinflunine given on a weekly schedule in previously untreated patients with advanced solid tumours. Proc Am Soc Clin Oncol 2003; 22:221 (Abstract 887).
27. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151
28. Yamamoto N, Tamura T, Maeda M, et al. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 1995; 36:102-106
29. Schellens JH, Ma J, Plantin AS, et al. Relationship between the exposure to cisplatin DANN-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996; 73:1569-1575
30. Committee for Proprietary Medicinal Products (CPMP) Note for guidance on the investigation of drug interactions. EMEA - CPMP/EWP/560/95; December 17, 1997.
31. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin ver-sus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360-367
32. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:3390-3399
33. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-3024
34. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic nonsmall- cell lung cancer. J Clin Oncol 2000; 18:122-130
35. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17:12-18
36. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17:3522-3530